Agendia to Provide First Digital MammaPrint Capability to Brazil
Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced that it is offering early access to its Digital MammaPrint platform for patients with breast cancer in Brazil, expanding the company’s offerings in the country with the goal of bringing essential information from cancer testing to the larger global breast cancer community. Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from genomic insights derived from a digitized image of a breast cancer tumor. Results about individual tumors will now be informed by the new artificial intelligence (AI) platform, also providing better turnaround time for their treatment decisions.
By offering Brazilian physicians and their patients early access to Digital MammaPrint test results, Agendia expects to be able to reach a patient population that includes the over 66,000 women in Brazil newly diagnosed with breast cancer in 2020 alone, enabling the possibility for earlier and faster intervention for these women along the entire continuum of care.1
“Incorporating AI into the MammaPrint equation for patients with early-stage breast cancer has the potential to be an unprecedented accelerator for the use of genomic testing and diagnostics in the treatment of this disease, and is potentially transformational for women with breast cancer around the world,” said Mark Straley, Chief Executive Officer of Agendia. “Stratifying breast cancer through AI analysis of a tumor tissue image trained by an astounding amount of our proprietary clinical data has the potential to fundamentally change how breast cancer is treated globally. Enabled by Agendia’s deep understanding and expertise in the functional genomics of breast cancer, we are proud to bring the robust science and clinical benefit that MammaPrint provides together with new digital capabilities, informed by the incredible power of AI, to Brazilian physicians and the women they seek to treat.”
Agendia’s Digital MammaPrint is powered by the cloud-based Paige Platform, a partnership that the two companies announced in November 2020. This is the first product of the collaboration, initially focused on the development of digital tests for early treatment planning where genomic testing has played a crucial role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead.
“Introducing Digital MammaPrint to physicians and their patients in Brazil marks an important step in increasing access to quality, AI-enabled diagnostic tests,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “We are excited to partner with Agendia to advance our shared goal of transforming pathology data into clear and actionable clinical insights for better patient outcomes.”
On a global scale, access to insights from Digital MammaPrint opens diagnostic care options for women diagnosed with breast cancer worldwide who don’t have access to genomic testing or esoteric lab infrastructure.
“For patients with breast cancer throughout the world who do not live in a location with direct access to genomic testing of their cancer, the ability to obtain such information from a slide image could be revolutionary. The introduction of a digital, AI-informed platform to allow interpretation of the genomic profile of their specific tumor can provide great clinical value and carries the added benefit of preserving valuable tumor tissue for further use in the future. We are using an innovative platform and doing revolutionary work with it,” said William Audeh, M.D., Chief Medical Officer at Agendia. “The ultimate goal is for patients to have access to vital information about their cancer, and this tool has the ability to provide them with that information faster, through digital technology. We believe that the sooner we can get MammaPrint insights into physicians’ hands in their decision-making process, the better it is for their patients.”
Agendia’s MammaPrint is a 70-gene prognostic test that stratifies a specific patient’s recurrence risk and provides a prognostic marker to help inform that risk along with other clinicopathologic factors. MammaPrint informs decisions about pre-operative systemic therapy, adjuvant chemotherapy, and adjuvant endocrine therapy, and the digital capabilities of the test are expected to give physicians and their patients clear and actionable information at these and other critical decision points throughout the cancer care continuum.
Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
1 Silva, J et.al. 25 Jan. 2021. Breast Cancer Mortality in Young Women in Brazil. Front. Oncol. 10:569933. Doi: 10.3389/fonc.2020.569933.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Westwicke/ICR Healthcare PR
For Agendia Investors:
Westwicke/ICR Healthcare IR
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GN launches new technology platform to address the No.1 hearing aid challenge: hearing speech in noise16.8.2022 09:00:00 CEST | Press release
GN Hearing, the global leader in hearing aid innovation, today announces the launch of ReSound OMNIA – a new hearing aid platform that will set a new standard in hearing technology and improve how people interact with the world around them. ReSound OMNIA provides significantly better hearing in noisy environments than any previous ReSound hearing aid. Coupled with optimal comfort and seamless connection to devices, these advances give people living with hearing loss a solution that will help them hear even the finest details of sound more easily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005068/en/ GN launches new technology platform to address the No.1 hearing aid challenge: hearing speech in noise (Photo: Business Wire) Despite advances in hearing aid technology over the last 10 years, hearing speech in noisy environments is still a challenge for people with hearing loss. In fact, 80% of people who wear hearing
Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection15.8.2022 19:42:00 CEST | Press release
Xlear has filed an Amended Answer in response to the U.S. Government’s lawsuit against the company. According to Nathan Jones, Xlear’s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of protection in fighting COVID-19, that our public health officials are ignoring; Second, it lays out in greater detail how the U.S. Government’s lawsuit is an effort to censor science that doesn’t comport with the Government’s vaccine-myopic, failing strategy to combat the disease; Third, it documents how experts, including Dr. Fauci, are increasingly saying the nose is the critical place to fight the virus. Xlear’s Amended Answer provides two new studies that support the statements Xlear made about the use of its nasal spray as a potential additional layer of protection against COVID-19: A new in vitro study found that use of a simple saline solution stops SAR-CoV2 vira
Energy Vault and Jupiter Power Announce Agreement for Battery Energy Storage Projects in Texas and California Totaling 220 MWh15.8.2022 14:00:00 CEST | Press release
Energy Vault Holdings Inc. (NYSE: NRGV) ("Energy Vault" or the “Company”), a leader in sustainable, grid-scale energy storage solutions, and Jupiter Power (“Jupiter”), a leading battery energy storage developer and owner/operator of utility-scale battery energy storage projects in the United States, today announced the signing of two contracts whereby Energy Vault will supply equipment, engineering, procurement, construction, balance of plant services and the energy management software for two of Jupiter’s battery energy storage projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220815005206/en/ The projects include a 100 MW (200 MWh) battery energy storage system near Fort Stockton, Texas, which will provide energy and ancillary services to ERCOT, and a 10 MW (20 MWh) system in Carpinteria, California, to provide grid services through participation in the CAISO Resource Adequacy program as well as energy resiliency in
euNetworks Delivers Sustainability Progress in Europe15.8.2022 09:50:00 CEST | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, continues to make strides in its sustainability efforts in Europe, both signing up to commitments and making meaningful and sustainable progress towards those targets. euNetworks joined The Climate Pledge in February 2022, setting 1.5°C-aligned science-based targets across Scopes 1, 2 and 3 and committing to being carbon net zero by 2040. The company has embedded its commitments in its company values and these drive the teams’ behaviour and form the basis by which the business operates. euNetworks has also developed and launched its Network Construction Carbon Tool to identify carbon hotspots, assess the incremental carbon impact of new projects, and reduce emissions across its supply chain. The impact of this tool is significant, as euNetworks owns and operates networks across 53 cities in 17 countries in Europe. This press release features multimedia. View the full release here: https://www.
A New Chapter in IT Services: Lenovo PCCW Solutions Starts First Day of Operation as a New Company15.8.2022 02:59:00 CEST | Press release
Today marks the first day of operation for Lenovo PCCW Solutions Limited1, the new strategic partnership between Lenovo Group (HKSE: 992) (ADR: LNVGY) and PCCW (HKSE: 0008) set to capitalize on the estimated US$320 billion Asia IT services market. The new company provides one-stop customer solutions that integrate IT services, devices, and digital infrastructure, and empowers clients to transform their businesses and operations with technology – from managing complex integrations to enhancing competitiveness with innovative applications. Through the partnership, the company benefits from Lenovo’s global footprint in more than 180 markets, broad portfolio of end-to-end solutions, solid pedigree in innovation, and strong go-to-market and delivery capabilities. Ken Wong, Executive Vice President of Lenovo and President of Lenovo Solutions and Services Group, said, “The partnership marks an important milestone in Lenovo’s service-led transformation journey since the formation of our Soluti